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Abstract: 
Objective: The objective of this case series was to determine if severe phantom limb 
pain could be reduced with oral methadone. 
Design: Four cases of phantom limb pain refractory to multiple treatment modalities 
were treated with oral methadone. 
Setting: Pain clinic at a major university medical center. 
Patients: Four patients with severe, intractable phantom limb pain. 
Intervention: Oral methadone was administered, starting with a low dose of 2 to 5 
mg twice a day or three times a day and slowly titrated upward to achieve pain relief. 
Outcome Measures: Repeated administration of a visual analog scale for pain. 
Results and Conclusions: Administration of oral methadone may be of value in the 
treatment of phantom limb pain; controlled clinical trials would be appropriate to 
verify this observation. 
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Phantom limb pain is referred neuropathic pain per-
ceived to arise from the part of the body that was am-
putated. The mechanisms of phantom limb pain remain 
unknown; both peripheral and central factors seem to be 
important. Recently, Floret al. postulated that a somato-
sensory pain memory and altered homonuclear structure 
in the somatosensory cortex may underlie phantom limb 
pain and that peripheral factors may sustain this 
memory.1 Suggested therapies include administration of 
pharmacological agents (e.g., antidepressive drugs, anti-
epileptic drugs, and calcitonin), behavioral interventions, 
transcutaneous electrical nerve stimulation, invasive 
techniques (e.g., epidural blockade, sympathectomies, 
dorsal root entry zone lesion, spinal cord stimulation, and 
motor cortex stimulation), and even electroconvulsive 
therapy?-5 In a significant percentage of amputees, ad-
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equate pain relief cannot be achieved, which makes the 
search for an effective therapy a priority. Not one of the 
many published treatments for phantom limb pain has 
been shown convincingly to be effective,4 necessitating 
the publication of even small case series. We report here 
on four patients with phantom limb pain refractory to 
multiple treatment strategies. The patients received 
methadone and all reported at least adequate relief of 
their phantom limb pain symptoms. 
CASE REPORTS 
Patient 1 
This patient was a 49-year-old woman who had a 
right above-elbow amputation due to arterial vascular 
occlusion of the right arm. After the amputation she suf-
fered stump pain, which subsided within a few days. 
Two weeks after surgery, the patient began complaining 
of phantom hand pain, which she described as feeling 
ice-cold and cramped. This pain increased in intensity 
over the following months despite treatment with trans-
cutaneous electrical nerve stimulation and medication 
(nonsteroidal antiinflammatory drugs, opioids [oral 
slow-release morphine], carbamazepine, amitriptyline, 
and calcitonin). 
Therapy with oral methadone was started 6 months 
after amputation. At that time, the patient rated her av-
erage phantom limb pain severity on a visual analog 
scale (VAS) as 7110. Two days after she began treatment 
with 5 mg methadone twice a day, the pain intensity 
decreased to a VAS score of 4/10. After 4 weeks, during 
which time the methadone dose was gradually increased 
to 7.5 mg twice a day and 10 mg as needed, she reported 
no pain during the day and pain with a VAS score of 4/10 
in the evening. On follow-up, 4 months after the start of 
therapy with methadone, the patient reported the absence 
of pain during the day and variable pain intensity in the 
evening, within a VAS score range of 4 to 8/10. 
Patient 2 
The second patient was a 47-year-old woman who had 
adenocarcinoma of unknown origin, with metastases to 
the right femur and to the brain. Because of the meta-
static cancer in her right femur, her right upper leg was 
amputated. 
Postoperatively the patient reported mild stump pain, 
which lasted for 2 days. After 1 week she began having 
phantom leg pain. The pain was treated medically, with 
opioids (intramuscular nicomorphine and transdermal 
fentanyl), amitriptyline, carbamazepine, valproic acid, 
and calcitonin. 
Four weeks after amputation a course of oral metha-
done was started. She rated her phantom limb pain in-
tensity at 6/10 before the start of this therapy. The initial 
dose of oral methadone (2 mg twice a day) was gradually 
increased to 6 mg twice a day and 8 mg as needed over 
a period of 3 months. At a 3-month follow-up, the patient 
reported substantial relief of the phantom limb pain, 
which she rated at 3/10. 
Patient 3 
The patient was a 21-year-old man who underwent a 
left above-the-knee amputation because of complex re-
gional pain syndrome type 1 of the left lower leg and 
foot. Two days after surgery, the patient started suffering 
severe phantom limb pain, rating the intensity as 9 to 
10/10 on a VAS. He also reported severe stump pain, 
rating it as 7110. Initially the patient was treated with 
nonsteroidal anti-inflammatory drugs, tramadol, opioids 
(intramuscular nicomorphine, oral slow-release mor-
phine, and transdermal fentanyl), amitriptyline, and 
gabapentin. Two weeks after amputation, therapy with 
oral methadone was started at a dosage of 2 mg three 
times a day. Within 3 days the patient reported dimin-
ished phantom limb pain but no relief of the stump pain. 
The dosage of methadone was increased to 5 mg four 
times a day over the next few days, and after 1 week the 
patient rated both his phantom pain and stump pain in-
tensity at 4/10. At this time, other opioids and gabapentin 
were withdrawn, and the patient's condition was main-
tained with a methadone dosage of 5 mg four times a day 
until follow-up. 
On follow-up 2 months later, the patient reported a 
VAS pain score of 4/10 for both phantom pain and stump 
pain. 
Patient 4 
This patient was a 27-year-old woman who had a 
right-upper-arm amputation because of recurrent upper-
arm luxation due to Ehlers-Danlos syndrome. Immedi-
ately after the amputation she suffered severe phantom 
hand pain, which she described as a burning and cramp-
ing sensation. Stump pain was present for only the first 4 
days postoperatively. 
Medical treatment of her phantom limb pain consisted 
of administration of nonsteroidal anti-inflammatory 
drugs, opioids (oral slow-release morphine and transder-
mal fentanyl), amitriptyline, and carbamazepine, several 
injections of calcitonin, and a continuous intravenous 
infusion of a low-dose ketamine. After 4 weeks of keta-
mine treatment, the patient still rated her phantom limb 
pain as 8/10. Ketamine was withdrawn and oral metha-
done (4 mg three times a day) was started. After 2 days, 
the patient reported pain relief. Over a period of 2 weeks, 
the methadone dosage was gradually increased to 10 mg 
four times a day. At that time the patient reported a VAS 
score of 3/10. 
Four months later, during which time the methadone 
administration was continued, she rated her phantom 
limb pain at 5110. An attempt to reduce the methadone 
dosage failed because of a subsequent increase in the 
severity of her phantom limb pain. 
DISCUSSION 
Methadone is a drug that was developed more than 40 
years ago. It is now mainly used both as a maintenance 
drug for opioid dependence and in the treatment of pain, 
mostly cancer pain.6 Some important characteristics of 
methadone are its lack of known metabolites, the long 
and unpredictable half-life, excellent absorption after 
oral and rectal administration, and its low cost. Because 
of its unpredictable half-life, methadone must be titrated 
carefully for each individual to avoid overdose. 
Four cases have been presented in which methadone 
reduced phantom limb pain. In all cases other medica-
tion, including opioids, did not result in satisfactory pain 
relief. No significant methadone-related side effects were 
noted in the four patients, a circumstance which we at-
tribute to the low doses and the slow titration rate. 
True phantom limb pain is a neuropathic pain 7 in 
which the process of central sensitization may play an 
important role.8 The N-methyl-D-aspartic acid (NMDA) 
receptor-ion channel is thought to be important in the 
development of central sensitization,9 and substances 
that block this receptor can be effective in the treatment 
of pain. 10 
In animal studies methadone acts as an opioid agonist 
as well as an NMDA-receptor antagonist/ 1 although it is 
not clear that the NMDA-receptor antagonist activity has 
any significance. 12 Still, a synergetic action between the 
opioid agonist activity and NMDA-receptor antagonist 
activity of methadone might contribute to its effective-
ness in the treatment of phantom limb pain. In this re-
spect it is remarkable that, in patient 4, the continuous 
infusion of ketamine did not produce any pain relief, 
whereas methadone dramatically decreased the phantom 
limb pain from an 8/10 score to a 3/10 score. 
In addition to its effects at the 1-1-opioid receptor and 
the NMDA receptor, methadone appears to inhibit sero-
tonin reuptake.13 It is known that serotonin plays a role 
in a variety of pain syndromes. The inhibition of sero-
tonin reuptake may therefore contribute to the analgesic 
effect of methadone in phantom limb pain, although we 
must mention that other serotonin reuptake inhibitors 
failed to produce pain relief in our patients. 
There are several limitations to the present case series. 
The series was nonrandomized, uncontrolled, and un-
blinded, and the follow-ups were limited to between 2 
and 4 months. The possibility of a placebo response can-
not be ruled out, but we think this is less likely since 
patients had been refractory to multiple other treatments. 
The limited follow-up times raise the possibility that the 
improvements we observed reflected the natural course 
of phantom limb pain, because the intensity and duration 
of phantom limb pain episodes appear to diminish during 
the first year after amputation. 14•15 
Nevertheless, prospective studies show that the inci-
dence of phantom limb pain is between 59% and 70% 1 
to 2 years after amputation/4 •15 and cross-sectional sur-
vey studies indicate that between 78% and 85% of am-
putees continue to experience significant phantom limb 
pain more than 25 years after amputation.4 Phantom limb 
pain occurs in the majority of amputees, and an effective 
treatment has yet to be found. We believe it is advisable 
to try treatment with oral methadone before considering 
invasive treatments. We realize that opioid therapy for 
chronic noncancer pain remains controversial because of 
concerns about tolerance and addiction. We suggest 
starting with a low dose of methadone (e.g., 2-5 mg 
twice a day or three times a day, depending on the se-
verity of the pain, body weight of the patient, and history 
of opioid use) and slowly titrating upward until satisfac-
tory pain relief is reached or intolerable side effects are 
noted. 
CONCLUSIONS 
Oral methadone was effective in reducing the intensity 
of phantom limb pain in four patients. All patients had 
tried a variety of other analgesic agents without effect. 
Given the high incidence of phantom limb pain and the 
immense suffering the pain engenders, it is imperative 
that effective treatments be found. A prospective, con-
trolled clinical trial evaluating the efficacy of methadone 
for phantom limb pain and addressing the issues of tol-
erance and addiction would be appropriate to verify our 
observations. 
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